| Literature DB >> 27743513 |
Pingnan Shan1, Zhiyong Lu1, Lihong Ye2, Yaqin Fang3, Suhong Tan1, Guohong Xuan1, Jincheng Ru1, Liming Mao1.
Abstract
BACKGROUND Prostatitis is a common and refractory urological disease with complicated etiology. Ureaplasma urealyticum (UU) has a close relationship with human urinary tract infection that can induce nonbacterial prostatitis. Tripterygium wilfordii polyglycoside (TWP) is a non-steroidal immune inhibitor that causes significant immune suppression and anti-inflammatory effects. Its role in prostatitis caused by UU has not yet been established. The aim of this study was to investigate the effect of TWP on UU-infected prostatitis in a rat model. MATERIAL AND METHODS UU-infected prostatitis SD model rats were randomly divided into 2 groups: the prostatitis group (model group) and the TWP treatment group (treatment group). At 7 days after treatment, prostate weight, leucocyte count, lecithin corpuscles, UU infection rate, and UU microbe count were compared between the 2 groups. Serum inflammatory cytokines TNF-α was determined by ELISA, and ICAM-1 and NF-κB expression were detected. RESULTS UU infection rate was 80% after modeling. The rat prostate weight and leucocyte count in the model group increased significantly, while lecithin corpuscles decreased. Compared with controls, inflammatory factor TNF-α, ICAM-1, and NF-κB expression were obviously higher (P<0.05). TWP markedly reduced prostate weight and leucocyte count, increased lecithin corpuscles, and decreased UU microbe count and TNF-α, ICAM-1, and NF-κB expression (P<0.05). CONCLUSIONS TWP can inhibit expression of inflammatory factors and may be useful in treating UU-infected prostatitis through reducing UU infection rate.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27743513 PMCID: PMC5070633 DOI: 10.12659/msm.897360
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Rat body and prostate weight change (χ̄±S).
| Group | n | Weight (g) | Prostate wet weight (g) | Wet prostate/body weight ratio |
|---|---|---|---|---|
| Control | 10 | 402±21.6 | 0.57±0.049 | 1.47×10−3 |
| Model group | 20 | 328±19.2 | 0.79±0.038 | 2.41×10−3 |
| Treatment group | 20 | 376±22.1 | 0.66±0.051 | 1.75×10−3 |
P<0.05, compared with control;
P<0.05, compared with model group.
Prostate white blood cell number and lecithin corpuscle density changes (χ̄±S).
| Group | n | WBC number (×109) | Lecithin corpuscle density | |||
|---|---|---|---|---|---|---|
| Level 1 | Level 2 | Level 3 | Level 4 | |||
| Control | 10 | 1.92±0.67 | 0 | 1 | 2 | 7 |
| Model group | 20 | 7.21±0.97 | 9 | 7 | 3 | 1 |
| Treatment group | 20 | 3.61±0.81 | 3 | 3 | 10 | 4 |
P<0.05, compared with control;
P<0.05, compared with model group.
UU microbe amount changes (χ̄±S).
| Group | n | Before treatment (CCU/ml) | After treatment (CCU/ml) |
|---|---|---|---|
| Model group | 20 | (6.2±0.8)×106 | (5.4±1.6)×106 |
| Treatment group | 20 | (6.4±0.6)×106 | (3.4±1.1)×103 |
P<0.05, compared with control;
P<0.05, compared with model group.
Figure 1Inflammatory factor expression (A) TNF-α; (B) ICAM-1; (C) NF-κB. * P<0.05, compared with control; # P<0.05, compared with model group.